

**Tumor Board Tuesday – Dr. Eleonora Teplinsky, 10/18/2022:
Early-stage Breast Cancer HER2+**

Posttest Rationale

- 1. What adjuvant therapy would you select for a patient with localized, HR-, HER2+ BC who had a pathologic complete response (R0 resection) after neoadjuvant TCH?**
 - a. T-DM1
 - b. TCH
 - c. Trastuzumab ± pertuzumab
 - d. Paclitaxel + trastuzumab

Rationale: The NCCN guidelines recommend adjuvant therapy with trastuzumab ± pertuzumab (up to 1 year) for patients with HR-/HER2+ and ypT0N0 or pCR after preoperative therapy. Adjuvant T-DM1 is recommended for those with ypT1–4N0 or ypN≥1. Adjuvant therapy with chemotherapy + trastuzumab (TCH or, for low-risk T1N0M0 or those ineligible for other regimens due to comorbidities, paclitaxel + trastuzumab) is recommended for those who did not receive systemic neoadjuvant therapy.

References: National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v4.2022). Updated June 21, 2022. Accessed August 1, 2022.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

- 2. What adjuvant treatment approach (FDA-approved therapy or clinical trial) would you select for a patient with early-stage breast cancer and residual disease after completion of HER2-targeted neoadjuvant therapy?**
 - a. T-DM1
 - b. T-DXd (CT)
 - c. TCH
 - d. TCHP

Rationale: T-DM1 is FDA approved and guidelines recommended for the adjuvant treatment of patients with residual invasive disease after neoadjuvant therapy. T-DXd is being evaluated in this setting and may be considered in the context of a clinical trial, ie, DESTINY-Breast05. TCH or TCHP are recommended in this setting if a patient discontinues T-DM1 for toxicity.

References: National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v4.2022). Updated June 21, 2022. Accessed August 1, 2022.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

ClinicalTrials.gov. A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05). NCT04622319. Updated May 4, 2022. Accessed May 19, 2020.
<https://clinicaltrials.gov/ct2/show/NCT04622319>